The global erectile dysfunction drugs
market is expected to reach USD 3.2 billion by 2022 according
to a new report by Grand View Research Inc. Rising adoption of sedentary
lifestyle and increasing prevalence of conditions causing erectile dysfunction
such as stress, hypertension, and related medications are the key factors expected
to widen the target population base for this market.
However, the market is
estimated to witness decline in revenue over the forecast period. Expiration of
key drugs from 2017 to 2019 is likely to curb revenue growth. On the other
hand, the market is likely to open up new avenues for the generic manufacturers
to capitalize on. The increasing risk of sexually transmitted diseases,
narrowing of insurance coverage for erectile dysfunction treatment, growing
threat from counterfeit drugs, and presence of social stigma in developing
countries are some factors limiting penetration rates.
Browse full report by Grand View
Research : http://www.grandviewresearch.com/industry-analysis/erectile-dysfunction-drugs-market
Further key findings from the report suggest:
·
Viagra accounted for over 47.0% of the total revenue in 2014. It
is generally considered as the first line of treatment for erectile dysfunction.
Brand loyalty and advantages associated with this drug such as high efficacy,
and effectiveness are the major factors attributing for its large market share.
·
Cialis (tadalafil) from Eli Lilly & Co. and Levitra
(vardenafil) from Bayer AG are known to be the competitors for Viagra globally.
Cialis (tadalafil) was approved in 2003 by the U.S. FDA, as a prescription drug
in the U.S. Cialis is also known as “The Weekend Pill” owing to its 36-hour
effectiveness.
·
After the patent expiration of key drugs such as Cialis
(tadalafil) in 2017 and Levitra (vardenafil) in 2018, other drugs such as
Stendra/Spedra, Zydena (udenafil), and Vitaros (Alprostadil Cream) are expected
to capture the market share during the forecasts period.
·
North America constituted the largest share of approximately
55.0% in 2013 of the total erectile dysfunction market. Extension of patent
exclusivity rights for Viagra (sildenafil citrate) in the U.S. till 2019 along
with introduction of new erectile dysfunction drugs such as Zydena (udenafil)
and Stendra/Spedra (avanafil) will be the major factors responsible for market
growth during the forecasts period.
·
Asia Pacific accounted for a revenue share of over 16.5% in 2012
owing to the presence of a lucrative market for generic drugs, untapped
opportunities, and increasing awareness related to erectile dysfunction in this
region
·
Apricus Biosciences Inc., Cristalia Produtos Quimicos
Farmaceuticos Ltd., Bayer AG, Dong-A Pharmaceutical Co. Ltd., Meda
Pharmaceuticals, Inc., Eli Lilly and Company, Pfizer, Inc., S.K. Chemicals Co.
Ltd., and Vivus, Inc. are some major players of this market
·
Extensive R&D carried out by companies and high unmet needs
in developing economies are expected to boost industrial growth. Key
manufacturers are targeting regions with unmet clinical needs by entering into
agreement with local manufacturers and distributors. Key players are constantly
engaged in developing novel drugs in an attempt to improve the presence and
ensure sustainability.
Browse more reports of this category by Grand View
Research: http://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has
segmented the global erectile dysfunction drugs market on the basis of product
and region:
Erectile Dysfunction Drugs Product Outlook (Revenue,
USD Million, 2012 – 2022)
·
Viagra (sildenafil citrate)
·
Cialis (tadalafil)
·
Levitra/Staxyn (vardenafil)
·
Stendra/Spedra (avanafil)
·
Zydena (udenafil)
·
Vitaros (Alprostadil Cream)
·
Others
Erectile Dysfunction Drugs Regional Outlook
(Revenue, USD Million, 2012 – 2022)
·
North America
·
Europe
·
Asia Pacific
·
RoW
Access press release by Grand View Research: http://www.grandviewresearch.com/press-release/global-erectile-dysfunction-drugs-market
About Grand View Research
Grand View Research,
Inc. is a U.S. based market research and consulting company, registered in the
State of California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
No comments:
Post a Comment